Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas

Context

  • Pancreatic Neuroendocrine Neoplasms (PanNENs): Heterogeneous group of epithelial tumors with neuroendocrine differentiation.

  • Classification:

    • Well-Differentiated Neuroendocrine Tumors (PanNETs): Subdivided into G1, G2, and G3 categories based on proliferative activity.

    • Poorly Differentiated Neuroendocrine Carcinomas (PanNECs): Defined as G3.

  • Classification is supported by clinical, histologic, and molecular data.

Objective

  • Summarize the neoplastic progression of PanNENs.

  • Understanding mechanisms may lead to new therapeutic strategies.

Data Sources

  • Reviews of literature and authors’ research findings.

Conclusions

  • PanNET G1-G2 tumors can progress to G3, influenced by DAXX/ATRX mutations and alternative lengthening of telomeres (ALT).

  • PanNECs possess different features related to pancreatic ductal adenocarcinoma, including TP53 and Rb alterations. They originate from non-neuroendocrine cells.

Prevalence

  • PanNENs account for approximately 2-3% of pancreatic malignancies.

Grading System for PanNETs

  • G1: ≤2 mitoses/2 mm², Ki-67 < 3%

  • G2: 2-20 mitoses/2 mm², Ki-67 3%-20%

  • G3: >20 mitoses/2 mm², Ki-67 > 20%

  • Morphological Features:

    • PanNETs: Organized architecture, hypercellular, "salt and pepper" chromatin, no necrosis.

    • PanNECs: Irregular nests, infiltrative growth, high-grade atypia, have necrosis.

Differences Between PanNETs and PanNECs

  • Behavior:

    • PanNETs: Indolent, slow-growing, may present with hormonal syndromes.

    • PanNECs: Aggressive, fast-growing, generally non-functional cancers.

  • Syndrome Association:

    • At least 10% of PanNETs are syndromic; PanNECs are usually sporadic.

Molecular Basis of Progression

  • G3 PanNETs share mutations with G1-G2 PanNETs (e.g., MEN1, DAXX/ATRX) but lack PanNEC-specific alterations (TP53, RB1).

  • Ki-67 Index:

    • G3 PanNETs show heterogeneous Ki-67.

    • PanNECs typically show high Ki-67 uniformly.

Biomarkers Predicting Aggressiveness

  • Presence of DAXX/ATRX mutations in about 40% of PanNETs linked to progression and advanced stages.

  • Loss of ATRX/DAXX correlates with shorter relapse-free survival.

  • ALT: Activates telomere maintenance, associated with poor prognosis and metastasis.

Role of Transcription Factors

  • ARX and PDX1: Influence endocrine cell differentiation and pancreatic islet lineage.

    • PDX1: Associated with indolent behavior.

    • ARX: Indicates aggressive disease course.

Distinction in Genetic Features

  • PanNECs: Reflect genetic alterations similar to Pancreatic Ductal Adenocarcinoma (PDAC) such as KRAS, TP53, and Rb1.

  • Latest studies classify PanNENs into two groups based on DNA methylation, with distinct profiles for high-grade PanNECs compared to PanNETs.

Precursor Lesions and Conclusions

  • No identified precursor lesions for PanNECs; however, precursor studies for PanNETs focus primarily on syndromic cases.

    • MEN1-related precursor lesions: Include microadenomas and endocrine cell clusters.

    • Tumor progression markers identified in syndromes such as von Hippel–Lindau.

  • Understanding these disparities is essential for developing therapies in precision oncology.